title: Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
abstract: Clear cell renal carcinoma (CCRC) is a highly angiogenic tumor known to secrete vascular endothelial cell growth factor (VEGF). Endostatin is an endogenous antiangiogenic agent with antitumor activity in mice. The purpose of this study was to evaluate serum levels of endostatin in normal subjects and in patients with CCRC and to examine the relationship of these levels to circulating VEGF levels. Fifteen patients (mean age, 48 years) on a clinical protocol for stage IV CCRC at the National Cancer Institute were included in the study. Archived prenephrectomy serum samples were analyzed for endostatin and VEGF concentrations. Endostatin and VEGF levels were compared with those of an age-matched group of volunteer blood donors (n = 18) using a competitive enzyme immunoassay. Data were analyzed using the Mann-Whitney U test and the Spearman rank correlation. Median serum endostatin levels were 24.6 ng/ml (range, 15.1-54.0 ng/ml) in CCRC patients versus 14.1 ng/ml (range, 1.0-19.3 ng/ml) in healthy controls (P < 0.0001). Median VEGF levels were 3.4 ng/ml (range, 0.1-11.2 ng/ml) and 2.5 ng/ml (range, 0.1-4.2 ng/ml), respectively (P = 0.065). A highly significant correlation was observed between endostatin and VEGF levels among the CCRC patients (r = 0.81, P = 0.0003) but not among controls (r = -0.22, P = 0.37). Endostatin levels are detectable in serum from healthy subjects as well as from CCRC patients. Levels are significantly elevated and correlate with VEGF levels in CCRC patients. Elucidating the nature of this correlation may lend insight into the regulation of tumor angiogenesis in patients with renal cancer.
authors.affiliation: Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.
authors.forename: A L
authors.initials: AL
authors.lastname: Feldman
authors.forename: L
authors.initials: L
authors.lastname: Tamarkin
authors.forename: G F
authors.initials: GF
authors.lastname: Paciotti
authors.forename: B W
authors.initials: BW
authors.lastname: Simpson
authors.forename: W M
authors.initials: WM
authors.lastname: Linehan
authors.forename: J C
authors.initials: JC
authors.lastname: Yang
authors.forename: W E
authors.initials: WE
authors.lastname: Fogler
authors.forename: E M
authors.initials: EM
authors.lastname: Turner
authors.forename: H R
authors.initials: HR
authors.lastname: Alexander
authors.forename: S K
authors.initials: SK
authors.lastname: Libutti
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000097:blood*; D000328:Adult; D000368:Aged; D015153:Blotting, Western; D016022:Case-Control Studies; D003094:Collagen / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D043169:Endostatins; D016228:Endothelial Growth Factors / Q000097:blood*; D005260:Female; D006801:Humans; D007118:Immunoassay; D007680:Kidney Neoplasms / Q000097:blood*; D008222:Lymphokines / Q000097:blood*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D009389:Neovascularization, Pathologic; D010446:Peptide Fragments / Q000097:blood*; D010641:Phenotype; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D043169:Endostatins; D016228:Endothelial Growth Factors; D008222:Lymphokines; D010446:Peptide Fragments; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D003094:Collagen